04:15 , Apr 13, 2018 |  BC Innovations  |  Targets & Mechanisms

Hello RNA

BioCentury’s analysis of new and emerging targets presented at this year’s AACR meeting reveals a surge in activity in non-coding RNAs, as researchers continue to expand target space. The results also reflect the ongoing high...
07:00 , Jul 16, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL); nuclear factor of κ light polypeptide gene enhancer in B cells 1 (NF-κB; NF

Cancer INDICATION: Lung cancer In vitro and mouse studies suggest TRAIL plus inhibition of either NF-κB, miR-21, miR-30c or miR-100 could help treat TRAIL-resistant lung cancer. Levels of NF-κB, miR-21, miR-30c and miR-100 were higher in TRAIL-resistant...
07:00 , Jul 18, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Various

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Various Atherosclerosis; hyperlipidemia MicroRNA-30c (miR-30c) Mouse and cell culture studies suggest miR-30c could...